Ying Jian Zhang

List of Publications by Year
in descending order

60 papers	1,317 citations	394421 19 h-index	377865 34 g-index
63 all docs	63 docs citations	63 times ranked	2372 citing authors

#	Article	IF	Citations
1	Development of High-Resolution Dedicated PET-Based Radiomics Machine Learning Model to Predict Axillary Lymph Node Status in Early-Stage Breast Cancer. Cancers, 2022, 14, 950.	3.7	20
2	Machine learning based on clinico-biological features integrated 18F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1538-1549.	6.4	30
3	18F-FDG PET/CT metabolic parameters and HER2 expression in colorectal cancer. Neoplasma, 2021, 68, 875-881.	1.6	0
4	18F-FLT PET/CT imaging for early monitoring response to CDK4/6 inhibitor therapy in triple negative breast cancer. Annals of Nuclear Medicine, 2021, 35, 600-607.	2.2	7
5	Combination of 99mTc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study. Cancer Management and Research, 2021, Volume 13, 2191-2199.	1.9	4
6	Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma. Annals of Nuclear Medicine, 2021, 35, 834-842.	2.2	8
7	Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer. International Journal of General Medicine, 2021, Volume 14, 1797-1809.	1.8	7
8	The clinical value of 18F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3956-3965.	2.0	14
9	Sentinel node theory helps tracking of primary lesions of cancers of unknown primary. BMC Cancer, 2020, 20, 639.	2.6	6
10	Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer. Frontiers in Oncology, 2020, 10, 580277.	2.8	12
11	Volumetric parameters derived from FLT-PET performed at completion of treatment predict efficacy of Carbon-ion Radiotherapy in patients with locally recurrent Nasopharyngeal Carcinoma. Journal of Cancer, 2020, 11, 7073-7080.	2.5	3
12	A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration. Clinical Cancer Research, 2020, 26, 4551-4558.	7.0	49
13	Mesoporous Bi-Containing Radiosensitizer Loading with DOX to Repolarize Tumor-Associated Macrophages and Elicit Immunogenic Tumor Cell Death to Inhibit Tumor Progression. ACS Applied Materials & Interfaces, 2020, 12, 31225-31234.	8.0	24
14	Preliminary results of targeted prostate‐specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration‐resistant prostate cancer. Cancer Medicine, 2020, 9, 3278-3286.	2.8	3
15	Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer. Scientific Reports, 2020, 10, 4179.	3.3	15
16	'Virtual experience' as an intervention before a positron emission tomography/CT scan may ease patients' anxiety and improve image quality. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 641-648.	1.8	5
17	The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer. Nuclear Medicine Communications, 2020, 41, 280-287.	1.1	3
18	Early prediction of tumor response after radiotherapy in combination with cetuximab in nasopharyngeal carcinoma using 99m Tc-duramycin imaging. Biomedicine and Pharmacotherapy, 2020, 125, 109947.	5.6	4

#	Article	IF	Citations
19	Establishment and validation of a nomogram with intratumoral heterogeneity derived from 18F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma. BMC Cancer, 2020, 20, 37.	2.6	18
20	The Predictive Value of Early Changes in 18F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. Oncologist, 2020, 25, 927-936.	3.7	20
21	Diagnostic classification of solitary pulmonary nodules using support vector machine model based on 2-[18F]fluoro-2-deoxy-D-glucose PET/computed tomography texture features. Nuclear Medicine Communications, 2020, 41, 560-566.	1.1	12
22	Characterization of heterogeneity of hypoxia with 18FMISO PET/CT, BOLD fMRI and immunohistochemistry in human breast tumor xenograft: initial study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, , .	0.7	1
23	Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal ¹⁸F-FES PET/CT. Contrast Media and Molecular Imaging, 2019, 2019, 1-8.	0.8	7
24	<p>Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a "PET biopsy"method</p>. Cancer Management and Research, 2019, Volume 11, 6019-6027.	1.9	3
25	Bone metastasis pattern of cancer patients with bone metastasis but no visceral metastasis. Journal of Bone Oncology, 2019, 15, 100219.	2.4	17
26	Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity. Clinical Cancer Research, 2019, 25, 3658-3672.	7.0	31
27	18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT. Oncologist, 2019, 24, e1277-e1285.	3.7	30
28	Long-acting octreotide treatment has no impact on tumor uptake of 99mTc-HYNIC-TOC in patients with neuroendocrine tumors. Nuclear Medicine Communications, 2019, 40, 1005-1010.	1.1	4
29	The quantitative carbohydrate ingestion ratio for extensive skeletal muscle uptake in 18F-FDG PET/computed tomography. Nuclear Medicine Communications, 2019, 40, 927-932.	1.1	0
30	Predictive Value of [18F]ML-10 PET/CT in Early Response Evaluation of Combination Radiotherapy with Cetuximab on Nasopharyngeal Carcinoma. Molecular Imaging and Biology, 2019, 21, 538-548.	2.6	7
31	The feasibility of 18F-FES and 18F-FDG microPET/CT for early monitoring the effect of fulvestrant on sensitizing docetaxel by downregulating ERα in ERα+ breast cancer. Annals of Nuclear Medicine, 2018, 32, 272-280.	2.2	2
32	Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study. Scientific Reports, 2018, 8, 14458.	3.3	16
33	Clinical application of 99mTc-HYNIC-TOC SPECT/CT in diagnosing and monitoring of pancreatic neuroendocrine neoplasms. Annals of Nuclear Medicine, 2018, 32, 446-452.	2.2	7
34	A novel, chelator-free method for 64Cu labeling of dendrimers. Journal of Nanoparticle Research, 2018, 20, 1.	1.9	7
35	Relationship between PSA kinetics and Tc€99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy. Prostate, 2018, 78, 1215-1221.	2.3	9
36	Amplifying Apoptosis Homing Nanoplatform for Tumor Theranostics. Advanced Healthcare Materials, 2018, 7, e1800296.	7.6	9

#	Article	IF	Citations
37	[99mTc]Tc-duramycin, a potential molecular probe for early prediction of tumor response after chemotherapy. Nuclear Medicine and Biology, 2018, 66, 18-25.	0.6	12
38	Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. Oncologist, 2018, 23, 1144-1152.	3.7	18
39	99m Tc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen. Nuclear Medicine and Biology, 2017, 48, 69-75.	0.6	38
40	A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. Scientific Reports, 2017, 7, 6584.	3.3	30
41	Textural features of 18F-FDG PET after two cycles of neoadjuvant chemotherapy can predict pCR in patients with locally advanced breast cancer. Annals of Nuclear Medicine, 2017, 31, 544-552.	2.2	27
42	$99m$Tc-labeled and gadolinium-chelated transferrin enhances the sensitivity and specificity of dual-modality SPECT/MR imaging of breast cancer. RSC Advances, 2016, 6, 20532-20541.	3.6	8
43	High specific activity is not optimal: 18Fâ€fluoroestradio positron emission tomographyâ€computed tomography results in a breast cancer xenograft. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 576-581.	1.0	4
44	MR/SPECT Imaging Guided Photothermal Therapy of Tumor-Targeting Fe@Fe$_3$O$_4$ Nanoparticles *in Vivo* with Low Mononuclear Phagocyte Uptake. ACS Applied Materials & Interfaces, 2016, 8, 19872-19882.	8.0	59
45	The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. Clinical Cancer Research, 2016, 22, 1603-1610.	7.0	37
46	Tumor Angiogenesis Targeted Radiosensitization Therapy Using Gold Nanoprobes Guided by MRI/SPECT Imaging. ACS Applied Materials & Interfaces, 2016, 8, 1718-1732.	8.0	67
47	Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer. PLoS ONE, 2016, 11, e0159916.	2.5	18
48	The preclinical study of predicting radiosensitivity in human nasopharyngeal carcinoma xenografts by 18F-ML-10 animal- PET/CT imaging. Oncotarget, 2016, 7, 20743-20752.	1.8	10
49	Hydrophilic Cu$_3$BiS$_3$ Nanoparticles for Computed Tomography Imaging and Photothermal Therapy. Particle and Particle Systems Characterization, 2015, 32, 668-679.	2.3	51
50	Graphene oxide-BaGdF5 nanocomposites for multi-modal imaging and photothermal therapy. Biomaterials, 2015, 42, 66-77.	11.4	140
51	Pretreatment 18â€‰F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinomaâ€"â€"a retrospective study. Radiation Oncology, 2015, 10, 4.	2.7	55
52	The Preliminary Study of 16Î±-[18F]fluoroestradiol PET/CT in Assisting the Individualized Treatment Decisions of Breast Cancer Patients. PLoS ONE, 2015, 10, e0116341.	2.5	36
53	18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer. Oncotarget, 2015, 6, 29388-29395.	1.8	24
54	Adding Maximum Standard Uptake Value of Primary Lesion and Lymph Nodes in 18F-Fluorodeoxyglucose PET Helps Predict Distant Metastasis in Patients with Nasopharyngeal Carcinoma. PLoS ONE, 2014, 9, e103153.	2.5	12

#	ARTICLE	IF	CITATIONS
55	Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. Clinical Imaging, 2014, 38, 470-474.	1.5	23
56	Clinical value of [18F]FDG-PET/CT in the detection of metastatic medullary thyroid cancer. Clinical Imaging, 2014, 38, 797-801.	1.5	8
57	Tungsten Oxide Nanorods: An Efficient Nanoplatform for Tumor CT Imaging and Photothermal Therapy. Scientific Reports, 2014, 4, 3653.	3.3	160
58	Can Positron Emission Tomography/Computed Tomography with the Dual Tracers Fluorine-18 Fluoroestradiol and Fluorodeoxyglucose Predict Neoadjuvant Chemotherapy Response of Breast Cancer? ----A Pilot Study. PLoS ONE, 2013, 8, e78192.	2.5	34
59	Automated synthesis of hypoxia imaging agent [18F]FMISO based upon a modified Explora FDG4 module. Journal of Radioanalytical and Nuclear Chemistry, 2009, 280, 149-155.	1.5	18
60	Study of radioimmunoimaging with monoclonal antibody against the patients with SCLC. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1991, 3, 56-57.	2.2	0